Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle

Pharmacology Research and Perspectives

Volumn 2, Issue 1, 2014, Pages 1-17

  Mele, Antonietta ^a   Calzolaro, Sara ^a   Cannone, Gianluigi ^a   Cetrone, Michela ^b   Conte, Diana ^a   Tricarico, Domenico ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Atrophy; Oral antidiabetic drugs; Pharmacovigilance; Skeletal muscle

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CASPASE 3; DIAZOXIDE; GLIBENCLAMIDE; NATEGLINIDE; REPAGLINIDE; STAUROSPORINE; SUCCINATE DEHYDROGENASE; SULFONYLUREA; TOLBUTAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SURFACE; BODY WEIGHT; CELL VIABILITY; CONTROLLED STUDY; DATA BASE; HOSPITALIZATION; MALE; MORPHOLOGICAL ADAPTATION; MORTALITY; MOUSE; MUSCLE ATROPHY; MUSCLE BIOPSY; NONHUMAN; PATCH CLAMP TECHNIQUE; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SKELETAL MUSCLE;

EID: 85026600748     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.28     Document Type: Article

References (37)

1. Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K, et al. (2010). Congenital hyperinsulinism. Early Hum Dev 86: 287-294.
2. Ashcroft FM (2010). New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab 11: 179-181.
3. Babenko AP, Gonzalez G, Bryan J (2000). Pharmaco-topology of sulfonylurea receptors. Separate domains of the regulatory subunits of K(ATP) channel isoforms are required for selective interaction with K(+) channel openers. J Biol Chem 275: 717-720.
4. Bonaldo P, Sandri M (2013). Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 6: 25-39.
5. De la Cadena SG, Hernández-Fonseca K, Camacho-Arroyo I, Massieu L (2013). Glucose deprivation induces reticulum stress by the PERK pathway and caspase-7- and calpain-mediated caspase-12 activation. Apoptosis. doi: 10.1007/s10495-013-0930-7
6. Diehl K-H, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. (2001). A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21: 15-23.
7. Dirks-Naylor AJ, Griffiths CL (2009). Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 117: 1-7.
8. Evans SJ, Aller PC, Davis S (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10: 483-486.
9. Fanzani A, Conraads VM, Penna F, Martinet W (2012). Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 3: 163-179. doi: 10.1007/s13539-012-0074-6
10. + channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56: 1930-1937.
11. Flechtner I, de Lonlay P, Polak M (2006). Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences. Diabetes Metab 6: 569-580.
12. Gribble FM, Reimann F (2003). Sulphonylurea action revisited: the post-cloning era. Diabetologia 46: 875-891.
13. Gribble FM, Tucker SJ, Seino S, Ashcroft FM (1998). Tissue Specificity of Sulfonylureas Studies on Cloned Cardiac and -Cell KAT P Channels. Diabetes 47: 1412-1418.
14. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wahlin-Boll E, Melander A, et al. (1991). Dose-Dependent Effects of Glyburide on Insulin Secretion and Glucose Uptake in Humans. Diabetes Care 14: 724-727.
15. Hambrock A, de Oliveira Franz CB, Hiller S, Osswald H (2006). Glibenclamide induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T). J Pharmacol Exp Ther 316: 1031-1037.
16. Jahangir A, Terzic A (2005). K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol 39: 99-112.
17. + channel (K ATP) connection. Diabetes 54: 3065-3072.
18. Kregiel D, Berlowska J, Ambroziak W (2008). Succinate Dehydrogenase Activity Assay in situ with Blue Tetrazolium Salt in Crabtree-Positive Saccharomyces cerevisiae Strain. Food Technol Biotechnol 46: 376-380.
19. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY (2005). Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90: 501-506.
20. Mele A, Buttiglione M, Cannone G, Vitiello F, Camerino DC, Tricarico D (2012). Opening/blocking actions of pyruvate kinase antibodies on neuronal and muscular KATP channels. Pharmacol Res 66: 401-408. doi: 10.1016/j.phrs.2012.07.007. Epub
21. Micromedex 2.0. (2012). Truven Health Analytics, Thomson Reuter.
22. Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, et al. (2007). Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 3: 640-645.
23. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM (2001). Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide. Circulation 103: 3111-3116.
24. Nichols CG, Singh GK, Grange DK (2013). KATP channels and cardiovascular disease: suddenly a syndrome. Circ Res 112: 1059-1072. doi: 10.1161/CIRCRESAHA.112.300514
25. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, et al. (2006). Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355: 467-477.
26. Pierno S, Tricarico D, Liantonio A, Mele A, Digennaro C, Rolland JF, et al. (2013). An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function. Age (Dordr). doi: 10.1007/s11357-013-9544-9
27. Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
28. Simard JM, Woo SK, Bhatta S, Gerzanich V (2008). Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol 8: 42-49.
29. Skalska J, Debska G, Kunz WS, Szewczyk A (2005). Antidiabetic sulphonylureas activate mitochondrial permeability transition in rat skeletal muscle. Br J Pharmacol 145: 785-791.
30. Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, Ikeda H, et al. (2007). Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta cell death in the chronic phase. Diabetes Res Clin Pract 77: 343-350.
31. Teshima Y, Akao M, Li RA, Chong TH, Baumgartner WA, Johnston MV, et al. (2003). Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule neurons from apoptosis induced by oxidative stress. Stroke 34: 1796-1802.
32. Tricarico D, Conte Camerino D (1994). ATP-sensitive K+ channels of skeletal muscle fibers from young adult and aged rats: possible involvement of thiol-dependent redox mechanisms in the age-related modifications of their biophysical and pharmacological properties. Mol Pharmacol 46: 754-761.
33. + channels determine their muscle-type-dependent biophysical and pharmacological properties. PNAS 103: 1118-1123.
34. Tricarico D, Mele A, Camerino GM, Bottinelli R, Brocca L, Frigeri A, et al. (2010). The KATP channel is a molecular sensor of atrophy in skeletal muscle. J Physiol 588: 773-784.
35. Valiyil R, Christopher-Stine L (2010). Drug-related Myopathies of Which the Clinician Should Be Aware. Curr Rheumatol Rep 12: 213-220.
36. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. (2013). and Gittes GK (2013) Hypoglycemia reduces vascular endothelial growth factor A production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem 288: 8636-8646. doi: 10.1074/jbc.M112.422949. Epub
37. Zünkler BJ (2006). Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther 112: 12-37.